It’s only fair to share… Lomedeucitinib CAS 2328068-29-5 MF C18H172H3N6O4S MW 419.5 g/mol 4-{[3-(methanesulfonyl)pyridin-2-yl]amino}-N-(2H3)methyl-6-[(1R)-spiro[2.2]pentane-1-carboxamido]pyridazine-3-carboxamide 4-[(3-methylsulfonyl-2-pyridinyl)amino]-6-[[(2R)-spiro[2.2]pentane-2-carbonyl]amino]-N-(trideuteriomethyl)pyridazine-3-carboxamideJanus kinase inhibitor, anti-inflammatory, BMS-986322, BMS 986322, EYQ7KA55XA Lomedeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis and psoriatic arthritis. It is a tyrosine kinase 2 (TYK2) inhibitor.[1] SYN US20210253554 https://patentscope.wipo.int/search/en/detail.jsf?docId=US333829535&_cid=P10-MHIXWK-98212-1 General Scheme for Examples 252 and 253: Example 252 Step 1 A mixture …